WC
NUVB icon

Wexford Capital’s Nuvation Bio NUVB Stock Holding History

Wexford Capital’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$519K Sell
120,889
-9,111
-7% -$50.8K 0.08% 79
2025
Q4 		$1.16M Buy
130,000
+99,672
+329% +$617K 0.22% 72
2025
Q3 		$112K Sell
30,328
-51,262
-63% -$140K 0.02% 221
2025
Q2 		$159K Sell
81,590
-691,329
-89% -$1.44M 0.04% 187
2025
Q1 		$1.36M Sell
772,919
-173,300
-18% -$394K 0.35% 59
2024
Q4 		$2.52M Buy
946,219
+294,452
+45% +$758K 0.4% 38
2024
Q3 		$1.49M Buy
651,767
+588,500
+930% +$1.79M 0.36% 53
2024
Q2 		$185K Buy
63,267
+37,982
+150% +$116K 0.05% 178
2024
Q1 		$92K Buy
25,285
+11,288
+81% +$21.7K 0.02% 206
2023
Q4 		$21.1K Sell
13,997
-25,105
-64% -$32.3K ﹤0.01% 192
2023
Q3 		$52.4K Buy
39,102
+13,402
+52% +$22.3K 0.01% 182
2023
Q2 		$46.3K Sell
25,700
-71,938
-74% -$122K 0.01% 189
2023
Q1 		$162K Buy
97,638
+74,638
+325% +$151K 0.03% 174
2022
Q4 		$44.2K Buy
+23,000
New +$46.5K 0.01% 129

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wexford Capital's NUVB Position: Q1 2026 in Review

Wexford Capital reduced its Nuvation Bio (NUVB) stake by 7% in Q1 2026, selling an estimated $50.8K and leaving 120,889 shares worth $519K. The position accounts for 0.08% of the portfolio, ranked #79.

Wexford Capital first reported a position in NUVB in Q4 2022 and has held it in 14 quarters since. The position peaked at $2.52M in Q4 2024. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Wexford Capital held 120,889 shares of Nuvation Bio worth $519K as of Q1 2026.
  • Wexford Capital sold 9,111 Nuvation Bio shares in Q1 2026, an estimated $50.8K.
  • Nuvation Bio made up 0.08% of Wexford Capital's portfolio in Q1 2026, its #79 holding.
  • Wexford Capital first reported a position in Nuvation Bio in Q4 2022 and has held it in 14 quarters since.
  • Wexford Capital's Nuvation Bio position peaked at $2.52M in Q4 2024.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Wexford Capital's 13F filing for Q1 2026, filed 15 May 2026.